Preparing for an ER Visit If you decide to go to the ER for stomach pain, preparation can help ensure a smoother experience
Closing: The Clinical Bottom Line on What Is MOTS-c MOTS-c is a mitochondrial-derived signaling peptide with a narrow, high-confidence clinical use case: amplifying AMPK-driven metabolic function in patients who have plateaued with diet, training, and standard interventions
The Role of Medical Supervision in Semaglutide Therapy Medical supervision is crucial during Semaglutide therapy
In short, for those who have faced barriers to injectable therapy, whether practical, psychological or social, a daily pill may open a door that was previously closed
The table below outlines the rare conditions that may occur when taking semaglutide: Hypoglycaemia (low blood sugar) is a risk in patients with type 2 diabetes

Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs
